As indicated above, increased expression of the A2aR on lymphocytes has been documented in patients with SLE, which suggests that targeting of the A2aR on T‐bet+ ABCs may be a viable approach to treat autoimmune diseases in patients [95]. This evidence concerns the gene ADORA2A and systemic lupus erythematosus.